Market Report, "United States Pharmaceuticals & Healthcare Report Q3 2012", Published
BMI View: The US pharmaceutical market is entering a period of relative stagnation. Patent expiries, fewer insured patients and greater use of rebates and discounts are creating severe headwinds to growth. A major downside risk is reduced tolerance for medicine price increases from payers, both public and private. We stress, however, that the US pharmaceutical market is still the most attractive globally, due to its large size and rapid uptake of newly approved innovative, and therefore high-priced, medicines.
View full press release